Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $47 from $50 and keeps an Overweight rating on the shares. The firm, which notes that timelines for lead programs in DMD and DM1 remain on track, views 2026 as “a year of execution.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
- Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
- Dyne Therapeutics announces upcoming presentations at MDA Conference
- Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
- Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference